RB1 and liposarcoma: In single‐agent studies, one phase II trial8 for well‐differentiated or dedifferentiated liposarcoma showed the median PFS was 4.5 months, which was 3.7 months in the phase II trial13 for Rb‐positive advanced breast cancer.